Vimarsana
Biggest News Aggregation in the World

Page 4 - Synact Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Synact Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Synact Pharma Today - Breaking & Trending Today

SynAct Pharma partners with Örebro University to study cardiovascular disease - Vimarsana News

SynAct Pharma partners with Örebro University to study cardiovascular disease

SynAct Pharma partners with Örebro University to study cardiovascular disease Publicerad: 12 maj 2021 13:37 Uppdaterad: 12 maj 2021 13:37 SynAct Pharma AB ("SynAct") today announced the company is a partner in a research project at Örebro University to study the reduction of inflammation in vascular disease. Dela på Facebook Uppdaterad: 12 maj 2021 13:37 The study, named “Targeting the melanocortin system as a novel strategy to reduce inflammation during vascular disease,” will be led Senior Lecturer Liza Ljungberg, School of Medical Sciences at Örebro University. The study i...

Source: breakit.se
SynAct Pharma: Interim report January-March 2021 - Vimarsana News

SynAct Pharma: Interim report January-March 2021

The Group's profit before tax amounted to -14,070 ( -3,822) TSEK. The Group's earnings per share amounted to -0.46 (-0.14). The average number of shares for the period was 25,366,295. "SynAct Pharma AB" means the parent company SynAct Pharma AB with corporate registration number 559058-4826. The "Company" or "SynAct" means the Group, i.e. SynAct Pharma AB and its wholly owned subsidiary SynAct Pharma ApS. definitions Earnings per share: Profit for the period divided by the average number of shares outstanding in the period. Equity/assets ratio: Equity divided by total capital. Significant ev...

Source: realtid.se
SynAct Pharma expands AP1189 BEGIN study in Rheumatoid Arthritis UK Version - Vimarsana News

SynAct Pharma expands AP1189 BEGIN study in Rheumatoid Arthritis UK Version

SynAct Pharma expands AP1189 BEGIN study in Rheumatoid Arthritis UK Version Lund, Sweden, May 4, 2021. SynAct Pharma AB ("SynAct") today announced that based upon the encouraging results seen in part 1 of the phase 2 clinical study BEGIN of AP1189, the company has decided to increase the study size in an effort to demonstrate statistical significance in the trial. SynAct Publicerad: 4 maj 2021, 08:00 Topline data from part 1 of the BEGIN study with AP1189 in early rheumatoid arthristis (RA) demonstrated a 66-74% treatment effect for the 50mg and 100mg dose groups respectively (Part 1 primary ...

Source: di.se
SynAct Pharma Board and Management extend lock-up period   UK Version - Vimarsana News

SynAct Pharma Board and Management extend lock-up period   UK Version

SynAct Pharma Board and Management extend lock-up period   UK Version SynAct Pharma AB ("SynAct") today announced all members of its board and management team have extended the lock-up period for their SynAct Pharma shares until December 31, 2021. In total the lock-up agreements correspond to more than 20 percent of the votes and capital in SynAct Pharma. Uppdaterad 2021-05-04 Publicerad 2021-05-04 “The members of the board and the entire management team have no intention of selling their shares now,” said Jeppe Øvlesen, CEO of SynA...

Source: realtid.se
Related Topics:
Synact Pharma
SynAct Pharma shareholders propose Marina Bozilenko as new board member - Vimarsana News

SynAct Pharma shareholders propose Marina Bozilenko as new board member

SynAct Pharma shareholders propose Marina Bozilenko as new board member SynAct Pharma AB ("SynAct") today announced that shareholders representing more than 20 per cent of the shares and votes in the company propose Marina Bozilenko to be elected as new board member of SynAct Pharma at the next annual general meeting set for May 21, 2021. Uppdaterad 2021-04-19 Publicerad 2021-04-19 Marina Bozilenko has more than 30 years of experience in investment banking and the healthcare industry, including raising more than $30 billion in capital and...

Source: realtid.se